Moderna Q2 Earnings Call Highlights Cost Cuts and Pipeline Milestones
MRNA keeps its 2026 growth target intact while cutting cost guidance and advancing flu, oncology and rare-disease programs toward key milestones.
Zacks
PFE, MRK, SNY, MRNA In Focus As Trump Reportedly Eyes Executive Order On Vaccines And Autism
The order’s contents remain unclear, and timing could shift, Bloomberg reported, citing people familiar with the matter.
Stocktwits
FDA approves Moderna mRNA flu shot
FDA approves Moderna mRNA flu shot...
CNBC Television-YouTube
MRNA Stock Pares Gains Despite FDA Green Light For First mRNA Flu Vaccine — But Retail Cheers Pivot Beyond COVID
The approval makes mFLUSIVA Moderna’s fourth FDA-cleared product and the first messenger RNA-based flu vaccine.
Stocktwits
Moderna's mRNA Flu Vaccine Approved By FDA
Moderna's mRNA Flu Vaccine Approved By FDA
Authored by Rachel Roberts via The Epoch Times,
The U.S. Food and Drug Administration has approved Moderna's flu shot for over-50s, marking the first time the agency has licensed a messenger ribonucleic acid (mRNA) vaccine for seasonal...
Zero Hedge
Beyond COVID: Moderna Wins FDA Approval for Its Seasonal Flu Vaccine
Moderna receives FDA approval for mFLUSIVA, a new seasonal flu vaccine for adults 50 and older, launching for the 2026-2027 virus season.read more...
Benzinga
U.S. FDA approves first mRNA flu shot from Moderna
The shot, mFlusiva, was given a traditional approval for adults aged 50 to 64, and an accelerated approval for those 65 years and older...
CNBC: Top News
Moderna Advances Ebola Vaccine Into Human Testing
Moderna starts Phase 1 trials for Ebola vaccine mRNA-1469. See premarket MRNA stock reaction, analyst updates, and ETF exposure.read more...